

Preventing Venous Thromboembolism in Surgical Oncology Patients (SON Newsletter page 6)

*Dr. Agnes YY Lee, Director, Thrombosis Program, Vancouver Coastal Health;
Associate Professor, Department of Medicine, UBC*

1. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. *J Thromb Haemost* 2007; 5(3):632-634.
2. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008; 133(6 Suppl):381S-453S.
3. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. *N Engl J Med* 1988; 318(18):1162-1173.
4. Horlocker TT, Wedel DJ, Benzon H et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). *Reg Anesth Pain Med* 2003; 28(3):172-197.
5. Leonardi MJ, McGory ML, Ko CY. A systematic review of deep venous thrombosis prophylaxis in cancer patients: implications for improving quality. *Ann Surg Oncol* 2007; 14(2):929-936.
6. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. *Br J Surg* 1997; 84(8):1099-1103.
7. Kakkar VV, Cohen AT, Edmonson RA et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group [see comments]. *Lancet* 1993; 341(8840):259-265.
8. McLeod RS, Geerts WH, Sniderman KW et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT

prophylaxis trial: a randomized, double-blind trial. *Ann Surg* 2001; 233(3):438-444.

9. Bergqvist D, Burmark US, Flordal PA et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients [see comments]. *Br J Surg* 1995; 82(4):496-501.
10. Balibrea JL, Altimiras J, Larruzea I, Gomez-Outes A, Martinez-Gonzalez J, Rocha E. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. *Int J Surg* 2007; 5(2):114-119.
11. Semrad TJ, O'Donnell R, Wun T et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. *J Neurosurg* 2007; 106(4):601-608.
12. Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. *Arch Intern Med* 2000; 160(15):2327-2332.
13. Perry JR, Rogers L, Laperriere N et al. PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. *J Clin Oncol* 2007;25[18S], abstract #2011.
14. Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. *Am J Obstet Gynecol* 1983; 145(5):606-613.
15. Einstein MH, Pritts EA, Hartenbach EM. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. *Gynecol Oncol* 2007; 105(3):813-819.
16. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008; 133(6 Suppl):454S-545S.
17. Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism

prophylaxis and treatment in patients with cancer. *J Clin Oncol* 2007; 25(34):5490-5505.

18. Bergqvist D, Agnelli G, Cohen AT et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. *N Engl J Med* 2002; 346(13):975-980.
19. Lausen I, Jensen R, Jorgensen LN et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. *Eur J Surg* 1998; 164(9):657-663.
20. Agnelli G, Bolis G, Capussotti L et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. *Ann Surg* 2006; 243(1):89-95.
21. Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. *Cochrane Database Syst Rev* 2000;(3):CD001484.
22. Turpie AG, Gallus A, Beattie WS, Hirsh J. Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. *Neurology* 1977; 27(5):435-438.
23. Kakkos SK, Caprini JA, Geroulakos G, Nicolaidis AN, Stansby GP, Reddy DJ. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. *Cochrane Database Syst Rev* 2008;(4):CD005258.